top-home.jpg

Starpharma signs license for VivaGel® Condom in Iran

Starpharma to present at Bio-Europe conference

Appendix 4C - Quarterly Cashflow Report

Additional Priostar® Glyphosate Patent Allowed in US

Starpharma to present at US Drug Delivery Conference

Sexual Health Drug Delivery Agrochemicals Wider Applications
         
 

Starpharma Holdings Limited is a world leader in the development of dendrimer products for pharmaceutical, life-science and other applications.

Starpharma’s lead products are based on VivaGel ® (SPL7013, astodrimer sodium), a proprietary dendrimer which has antimicrobial properties.  VivaGel® formulated as a water based gel and delivered vaginally now has EU regulatory approval for topical treatment and rapid relief of bacterial vaginosis (BV) and is under clinical development for the prevention of recurrent BV.  Starpharma has also signed separate licence agreements with Ansell Limited and Okamoto Industries. Inc., to market a value-added, VivaGel® condom. The VivaGel® condom is available for purchase in Australia under Ansell’s Lifestyles® Dual Protect TM  brand.  

In the wider pharmaceutical field, Starpharma has both partnered and internal programs in Drug Delivery.

 

 A number of dendrimer-enhanced, or DEP® versions of existing drugs are under development. The most advanced of these is DEP® docetaxel, a dendrimer-enhanced version of docetaxel (Taxotere®), which is in clinical development in patients with solid tumours. In preclinical studies DEP® docetaxel has shown significant tumour-targeting and superior anti-cancer effects across a range of important cancer types including breast, prostate, lung and ovarian tumour, when compared to Taxotere® (docetaxel). AstraZeneca has signed a licensing agreement with Starpharma for the use of its DEP® drug delivery platform in the development and commercialisation of an AstraZeneca oncology compound, with potential for follow on compounds directed at a defined family of targets.

In agrochemicals Starpharma has a series of partnerships with leading industry players including global leader Adama (formerly Makhteshim Agan) as well as internal programs including an enhanced version of glyphosate.

 
         

invester-center.jpg

DEPclinical__220x125_.jpg

Code Last $+/-
SPL 0.720 0.000

Data provided by asx.com.au. Prices are delayed by at least 20 minutes.

© Starpharma Holdings Limited 2016